Integrated digital error suppression for improved detection of circulating tumor DNA

Nature Biotechnology

Volumn 34, Issue 5, 2016, Pages 547-555

  Newman, Aaron M ^a   Lovejoy, Alexander F ^a,b,c,e   Klass, Daniel M ^a,c,e   Kurtz, David M ^a,d   Chabon, Jacob J ^a   Scherer, Florian ^a   Stehr, Henning ^c   Liu, Chih Long ^a   Bratman, Scott V ^a,b   Say, Carmen ^b   Zhou, Li ^c   Carter, Justin N ^b   West, Robert B ^a   Sledge, George W ^a,c   Shrager, Joseph B ^a   Loo, Billy W ^b   Neal, Joel W ^a   Wakelee, Heather A ^a   Diehn, Maximilian ^a,b   Alizadeh, Ash A ^a,c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

^c STANFORD CANCER INSTITUTE   (United States)

^d Stanford University   (United States)

^e ROCHE MOLECULAR SYSTEMS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIGITAL INTEGRATED CIRCUITS; DISEASES; DNA; MOLECULES; TUMORS;

CANCER THERAPY; CELL-FREE; CLINICAL SETTINGS; ERROR SUPPRESSION; GENOTYPING; HIGH-THROUGHPUT SEQUENCING; KINASE DOMAINS; NON SMALL CELL LUNG CANCER;

GENE ENCODING;

CIRCULATING TUMOR DNA; DNA; DOUBLE STRANDED DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; TUMOR MARKER;

ARTICLE; ARTIFACT; CANCER PATIENT; COMPUTER MODEL; DNA BARCODING; DNA SEQUENCE; GENE MUTATION; GENOTYPE; HIGH THROUGHPUT SEQUENCING; HUMAN; HUMAN TISSUE; LIMIT OF DETECTION; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SOMATIC MUTATION; ALGORITHM; BLOOD; GENETICS; ISOLATION AND PURIFICATION; METABOLISM; PROCEDURES; REPRODUCIBILITY; SIGNAL PROCESSING; SYSTEM ANALYSIS; TUMOR EMBOLISM;

ALGORITHMS; ARTIFACTS; BIOMARKERS, TUMOR; DNA, NEOPLASM; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; NEOPLASTIC CELLS, CIRCULATING; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SIGNAL PROCESSING, COMPUTER-ASSISTED; SYSTEMS INTEGRATION;

EID: 84966365311     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.3520     Document Type: Article

References (49)

1. Heitzer, E., Ulz, P., Geigl, J.B. Circulating tumor DNA as a liquid biopsy for cancer. Clin. Chem. 61, 112-123 (2015).
2. Diehl, F. et al. Circulating mutant DNA to assess tumor dynamics. Nat. Med. 14, 985-990 (2008).
3. Bettegowda, C. et al. Detection of circulating tumor DNA in early-and late-stage human malignancies. Sci. Transl. Med. 6, 224-24 (2014).
4. Bratman, S.V., Newman, A.M., Alizadeh, A.A., Diehn, M. Potential clinical utility of ultrasensitive circulating tumor DNA detection with CAPP-Seq. Expert Rev. Mol. Diagn. 15, 715-719 (2015).
5. Diaz, L.A. Jr., Bardelli, A. Liquid biopsies: genotyping circulating tumor DNA. J. Clin. Oncol. 32, 579-586 (2014).
6. Kurtz, D.M. et al. Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. Blood 125, 3679-3687 (2015).
7. Butler, T.M. et al. Exome sequencing of cell-free DNA from metastatic cancer patients identifies clinically actionable mutations distinct from primary disease. PLoS One 10, e0136407 (2015).
8. Newman, A.M. et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat. Med. 20, 548-554 (2014).
9. Taniguchi, K. et al. Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas. Clin. Cancer Res. 17, 7808-7815 (2011).
10. Jabara, C.B., Jones, C.D., Roach, J.,erson, J.A., Swanstrom, R. Accurate sampling and deep sequencing of the HIV-1 protease gene using a Primer ID. Proc. Natl. Acad. Sci. USA 108, 20166-20171 (2011).
11. Kinde, I., Wu, J., Papadopoulos, N., Kinzler, K.W., Vogelstein, B. Detection and quantification of rare mutations with massively parallel sequencing. Proc. Natl. Acad. Sci. USA 108, 9530-9535 (2011).
12. Schmitt, M.W. et al. Detection of ultra-rare mutations by next-generation sequencing. Proc. Natl. Acad. Sci. USA 109, 14508-14513 (2012).
13. Kennedy, S.R. et al. Detecting ultralow-frequency mutations by Duplex Sequencing. Nat. Protoc. 9, 2586-2606 (2014).
14. Gregory, M.T. et al. Targeted single molecule mutation detection with massively parallel sequencing. Nucleic Acids Res. 44, e22 (2016).
15. Kukita, Y. et al. High-fidelity target sequencing of individual molecules identified using barcode sequences: de novo detection and absolute quantitation of mutations in plasma cell-free DNA from cancer patients. DNA Res. 22, 269-277 (2015).
16. Lou, D.I. et al. High-throughput DNA sequencing errors are reduced by orders of magnitude using circle sequencing. Proc. Natl. Acad. Sci. USA 110, 19872-19877 (2013).
17. Schmitt, M.W. et al. Sequencing small genomic targets with high efficiency and extreme accuracy. Nat. Methods 12, 423-425 (2015).
18. De Mattos-Arruda, L. et al. Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat. Commun. 6, 8839 (2015).
19. Costello, M. et al. Discovery and characterization of artifactual mutations in deep coverage targeted capture sequencing data due to oxidative DNA damage during sample preparation. Nucleic Acids Res. 41, e67 (2013).
20. Chen, G., Mosier, S., Gocke, C.D., Lin, M.T., Eshleman, J.R. Cytosine deamination is a major cause of baseline noise in next-generation sequencing. Mol. Diagn. Ther. 18, 587-593 (2014).
21. Leon, S.A., Shapiro, B., Sklaroff, D.M., Yaros, M.J. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 37, 646-650 (1977).
22. Hafner, C. et al. Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern. Proc. Natl. Acad. Sci. USA 104, 13450-13454 (2007).
23. Higgins, M.J. et al. Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood. Clin. Cancer Res. 18, 3462-3469 (2012).
24. Sequist, L.V. et al. Rociletinib in EGFR-mutated non-small-cell lung cancer. N. Engl. J. Med. 372, 1700-1709 (2015).
25. Oxnard, G.R. et al. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin. Cancer Res. 20, 1698-1705 (2014).
26. Pao, W. et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. USA 101, 13306-13311 (2004).
27. Pao, W. et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2, e73 (2005).
28. Sequist, L.V. et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med. 3, 75-26 (2011).
29. Douillard, J.Y. et al. Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status. J. Thorac. Oncol. 9, 1345-1353 (2014).
30. Mok, T. et al. Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib and chemotherapy. Clin. Cancer Res. 21, 3196-3203 (2015).
31. Misale, S. et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486, 532-536 (2012).
32. Murtaza, M. et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 497, 108-112 (2013).
33. Thress, K.S. et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat. Med. 21, 560-562 (2015).
34. Marchetti, A. et al. Early prediction of response to tyrosine kinase inhibitors by quantification of EGFR mutations in plasma of NSCLC patients. J. Thorac. Oncol. 10, 1437-1443 (2015).
35. Dawson, S.J. et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N. Engl. J. Med. 368, 1199-1209 (2013).
36. Garcia-Murillas, I. et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci. Transl. Med. 7, 302ra133 (2015).
37. Roschewski, M. et al. Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. Lancet Oncol. 16, 541-549 (2015).
38. Samorodnitsky, E. et al. Evaluation of hybridization capture versus amplicon-based methods for whole-exome sequencing. Hum. Mutat. 36, 903-914 (2015).
39. Drilon, A. et al. Broad, hybrid capture-based next-generation sequencing identifies actionable genomic alterations in lung adenocarcinomas otherwise negative for such alterations by other genomic testing approaches. Clin. Cancer Res. 21, 3631-3639 (2015).
40. Rehm, H.L. et al. ACMG clinical laboratory standards for next-generation sequencing. Genet. Med. 15, 733-747 (2013).
41. Ellis, P.M., Verma, S., Sehdev, S., Younus, J., Leighl, N.B. Challenges to implementation of an epidermal growth factor receptor testing strategy for non-small-cell lung cancer in a publicly funded health care system. J. Thorac. Oncol. 8, 1136-1141 (2013).
42. Leighl, N.B. et al. Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline. J. Clin. Oncol. 32, 3673-3679 (2014).
43. Lim, C. et al. Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer. Ann. Oncol. 26, 1415-1421 (2015).
44. Shiau, C.J. et al. Sample features associated with success rates in population-based EGFR mutation testing. J. Thorac. Oncol. 9, 947-956 (2014).
45. Yatabe, Y. et al. EGFR mutation testing practices within the Asia Pacific region: results of a multicenter diagnostic survey. J. Thorac. Oncol. 10, 438-445 (2015).
46. Hindson, B.J. et al. High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. Anal. Chem. 83, 8604-8610 (2011).
47. Forbes, S.A. et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res. 43, D805-D811 (2015).
48. Su, Z. et al. A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer. J. Mol. Diagn. 13, 74-84 (2011).
49. Lambert, D. Zero-inflated poisson regression, with an application to defects in manufacturing. Technometrics 34, 1-14 (1992).